Elisa Agostinetto: Camizestrant vs Fulvestrant for estrogen receptor-positive, HER2-negative breast cancer
Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared an article by Mafalda Oliveira on X, adding:
“Results of SERENA-2 are out in the Lancet Oncology.
The oral SERD camizestrant showed PFS vs. fulvestrant, supporting further development of camizestrant for the treatment of estrogen receptor-positive, HER2-negative breast cancer.”
Authors: Mafalda Oliveira, et al.
Elisa Agostinetto, is a medical oncologist, specializing in breast cancer research. Elisa Agostinetto is a Medical Research Fellow at the University Hospital of Brussels since November 2021. Additionally, she has serves as a Clinical Research Fellow at Jules Bordet Institute. Her work focuses on clinical research in oncology, likely involving various aspects of cancer treatment and patient care. Actively engaged in professional societies like ESMO, ASCO, and BSMO, she also contributes as a young investigator in the EORTC Breast Cancer Working Group and as a Committee member of the Young Cancer Professionals within the European Cancer Organization.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023